Illumina, Inc. (ILMN) Expected to Announce Quarterly Sales of $886.93 Million

Equities research analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will post sales of $886.93 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Illumina’s earnings. The highest sales estimate is $890.00 million and the lowest is $881.98 million. Illumina posted sales of $830.00 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.9%. The business is expected to announce its next quarterly earnings report on Monday, July 29th.

According to Zacks, analysts expect that Illumina will report full-year sales of $3.76 billion for the current financial year, with estimates ranging from $3.71 billion to $3.80 billion. For the next year, analysts forecast that the company will post sales of $4.31 billion, with estimates ranging from $4.22 billion to $4.54 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Illumina.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. During the same quarter last year, the business earned $1.45 EPS. The business’s revenue was up 8.2% on a year-over-year basis.

A number of brokerages have recently issued reports on ILMN. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Canaccord Genuity reiterated a “buy” rating and issued a $350.00 price target (down previously from $360.00) on shares of Illumina in a report on Friday, April 26th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a report on Tuesday, April 2nd. OTR Global downgraded shares of Illumina to a “positive” rating in a report on Tuesday, April 2nd. Finally, Bank of America reiterated a “buy” rating and issued a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Illumina has a consensus rating of “Buy” and a consensus target price of $353.58.

In other Illumina news, Director Robert S. Epstein sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $313.93, for a total transaction of $313,930.00. Following the completion of the transaction, the director now directly owns 4,256 shares in the company, valued at approximately $1,336,086.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $321.96, for a total transaction of $1,062,468.00. The disclosure for this sale can be found here. Insiders have sold a total of 42,126 shares of company stock valued at $13,073,922 over the last 90 days. 0.38% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 39 shares in the last quarter. First Manhattan Co. increased its holdings in Illumina by 18.8% during the 1st quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock valued at $1,076,000 after acquiring an additional 547 shares in the last quarter. Sapphire Star Partners LP purchased a new position in Illumina during the 4th quarter valued at about $360,000. Machina Capital S.A.S. purchased a new position in Illumina during the 4th quarter valued at about $1,099,000. Finally, Ardevora Asset Management LLP increased its holdings in Illumina by 14.2% during the 1st quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock valued at $31,446,000 after acquiring an additional 12,600 shares in the last quarter. Hedge funds and other institutional investors own 90.80% of the company’s stock.

Shares of ILMN opened at $315.81 on Monday. The company has a quick ratio of 3.33, a current ratio of 3.66 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $46.42 billion, a PE ratio of 55.21, a P/E/G ratio of 2.21 and a beta of 1.15. Illumina has a 52-week low of $261.61 and a 52-week high of $372.61.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Recommended Story: Cost of Capital

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.